Mickey C-T Hu
Overview
Explore the profile of Mickey C-T Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Z, Hu M, Hsu C, Wu Y, Lu Y, Ho J, et al.
Cancer Lett
. 2023 Jan;
556:216063.
PMID: 36669725
The telomerase-specific oncolytic adenovirus Telomelysin and the histone deacetylase inhibitor AR42 have demonstrated anticancer effects in preclinical models of human hepatocellular carcinoma (HCC). However, the clinical development of Telomelysin may...
2.
Lee Y, Chen Y, Ou D, Hsu C, Liu J, Ko J, et al.
J Pathol
. 2023 Jan;
259(4):428-440.
PMID: 36641765
Anti-programmed cell death 1 (anti-PD-1) therapy shows definite but modest activity in patients with advanced/metastatic head and neck squamous cell carcinoma (HNSCC). Preliminary evidence suggests that SN-38, an activated form...
3.
Chung Y, Tsai W, Khan P, Ma J, Berek J, Larrick J, et al.
Am J Cancer Res
. 2022 Apr;
12(3):1241-1263.
PMID: 35411241
Boosting anticancer immunity by blocking immune checkpoints such as the programmed death-1 (PD-1) or its ligand (PD-L1) is a breakthrough anticancer therapy. However, many cancer patients do not respond well...
4.
Chung Y, Khan P, Wang H, Tsai W, Qiao Y, Yu B, et al.
J Immunother Cancer
. 2021 Dec;
9(12).
PMID: 34887262
Background: Stimulating antitumor immunity by blocking programmed death-1 (PD-1) or its ligand (programmed death-ligand 1 (PD-L1) is a promising antitumor therapy. However, numerous patients respond poorly to PD-1/PD-L1 blockade. Unresponsiveness...
5.
Lin Z, Hsu C, Jeng Y, Hu F, Pan H, Wu Y, et al.
Liver Int
. 2019 Jan;
39(9):1682-1691.
PMID: 30698907
Background And Aims: Fibroblast growth factor 19 (FGF19) and fibroblast growth factor receptor 4 (FGFR4) signalling play critical roles in hepatocarcinogenesis. This study explored the potential of FGF19- and FGFR4-related...
6.
Park S, Chung Y, Ma J, Yang Q, Berek J, Hu M
Oncotarget
. 2016 Jun;
7(27):42110-42125.
PMID: 27283899
Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer. Lacking effective therapeutic options hinders treatment of TNBC. Here, we show that bepridil (BPD) and trifluoperazine (TFP), which...
7.
Pfeifer D, Chung Y, Hu M
Environ Health Perspect
. 2015 May;
123(12):1271-9.
PMID: 25933419
Background: Humans are exposed to low-dose bisphenol A (BPA) through plastic consumer products and dental sealants containing BPA. Although a number of studies have investigated the mammary gland effects after...
8.
Chen M, Zhou B, Zhang K, Yuan Y, Un F, Hu S, et al.
Mol Pharmacol
. 2015 Mar;
87(6):996-1005.
PMID: 25814515
COH29 [N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide], a novel antimetabolite drug developed at City of Hope Cancer Center, has anticancer activity that stems primarily from the inhibition of human ribonucleotide reductase (RNR). This key enzyme...
9.
Park S, Lee J, Berek J, Hu M
Int J Oncol
. 2014 Aug;
45(4):1691-8.
PMID: 25096914
Auranofin is a gold-containing compound classified by the World Health Organization as a clinically established rheumatoid arthritis therapeutic agent. Through drug screening for novel anticancer therapeutics, we unexpectedly identified auranofin...
10.
Hu T, Chung Y, Guan M, Ma M, Ma J, Berek J, et al.
Sci Rep
. 2014 Jul;
4:5810.
PMID: 25056111
Cancer is a leading cause of death worldwide. Because the cytotoxic effects of conventional chemotherapies often harm normal tissue cells along with cancer cells, conventional chemotherapies cause many unwanted or...